Skye Bioscience Investor Relations Material

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic solutions targeting the endocannabinoid system (ECS). The company's primary focus is on conditions such as obesity, chronic kidney disease, and glaucoma. Skye's portfolio includes drug candidates like nimacimab, a monoclonal antibody that acts as a CB1 receptor inhibitor, and SBI-100 Ophthalmic Emulsion, designed to reduce intraocular pressure in glaucoma patients. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.